A therapeutic substitution policy that was expected to save the B.C. government $42 million has instead cost the health care system $43.5 million, says a new study.
Stronger evidence supports the use of lithium rather than olanzapine as a first-line maintenance treatment of bipolar disorder, according to new research.
